JP Morgan Chase’s Coherus Oncology CHRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$85K Buy
53,156
+2,000
+4% +$3.55K ﹤0.01% 5918
2025
Q4
$72.6K Sell
51,156
-56,445
-52% -$82.3K ﹤0.01% 6067
2025
Q3
$176K Buy
107,601
+5,821
+6% +$6.47K ﹤0.01% 5582
2025
Q2
$74.4K Sell
101,780
-121,345
-54% -$105K ﹤0.01% 5740
2025
Q1
$180K Buy
223,125
+173,384
+349% +$200K ﹤0.01% 5283
2024
Q4
$68.6K Sell
49,741
-11,642
-19% -$13.1K ﹤0.01% 5894
2024
Q3
$63.8K Buy
61,383
+1,073
+2% +$1.47K ﹤0.01% 5899
2024
Q2
$104K Sell
60,310
-166,769
-73% -$336K ﹤0.01% 5497
2024
Q1
$543K Sell
227,079
-208,587
-48% -$513K ﹤0.01% 4739
2023
Q4
$1.45M Sell
435,666
-4,944,542
-92% -$13.2M ﹤0.01% 4079
2023
Q3
$20.1M Sell
5,380,208
-348,710
-6% -$1.61M ﹤0.01% 1675
2023
Q2
$24.5M Sell
5,728,918
-253,617
-4% -$1.5M ﹤0.01% 1550
2023
Q1
$40.9M Sell
5,982,535
-522,328
-8% -$4.05M 0.01% 1197
2022
Q4
$51.5M Buy
6,504,863
+379,618
+6% +$2.92M 0.01% 1099
2022
Q3
$58.9M Sell
6,125,245
-360,986
-6% -$3.65M 0.01% 973
2022
Q2
$47M Sell
6,486,231
-89,312
-1% -$777K 0.01% 1074
2022
Q1
$84.9M Sell
6,575,543
-114,205
-2% -$1.45M 0.01% 915
2021
Q4
$107M Sell
6,689,748
-481,119
-7% -$8.41M 0.01% 851
2021
Q3
$115M Buy
7,170,867
+1,076,809
+18% +$15.8M 0.01% 797
2021
Q2
$84.3M Buy
6,094,058
+897,952
+17% +$12.7M 0.01% 972
2021
Q1
$75.9M Buy
5,196,106
+242,524
+5% +$4.12M 0.01% 975
2020
Q4
$86.1M Buy
4,953,582
+223,225
+5% +$3.97M 0.01% 834
2020
Q3
$89M Buy
4,730,357
+192,453
+4% +$3.58M 0.02% 736
2020
Q2
$81M Buy
4,537,904
+413,659
+10% +$7M 0.02% 721
2020
Q1
$66.9M Buy
4,124,245
+666,775
+19% +$12.3M 0.02% 706
2019
Q4
$62.3M Sell
3,457,470
-215,176
-6% -$3.97M 0.01% 853
2019
Q3
$74.4M Sell
3,672,646
-591,159
-14% -$11.8M 0.01% 776
2019
Q2
$91.6M Sell
4,263,805
-478,784
-10% -$8.32M 0.02% 704
2019
Q1
$64.7M Buy
4,742,589
+1,010,708
+27% +$13.5M 0.01% 838
2018
Q4
$33.8M Buy
3,731,881
+1,543,553
+71% +$17.9M 0.01% 1112
2018
Q3
$36.1M Sell
2,188,328
-44,570
-2% -$790K 0.01% 1224
2018
Q2
$31.3M Buy
2,232,898
+187,830
+9% +$2.69M 0.01% 1266
2018
Q1
$22.6M Buy
2,045,068
+120,574
+6% +$1.32M ﹤0.01% 1429
2017
Q4
$16.9M Buy
1,924,494
+173,292
+10% +$1.86M ﹤0.01% 1701
2017
Q3
$23.6M Buy
1,751,202
+359,491
+26% +$4.76M 0.01% 1393
2017
Q2
$20M Sell
1,391,711
-238,776
-15% -$4.59M ﹤0.01% 1452
2017
Q1
$34.5M Buy
1,630,487
+65,619
+4% +$1.61M 0.01% 1133
2016
Q4
$44.1M Sell
1,564,868
-366,111
-19% -$10.2M 0.01% 962
2016
Q3
$51.7M Buy
1,930,979
+54,042
+3% +$1.47M 0.01% 813
2016
Q2
$31.7M Sell
1,876,937
-245,614
-12% -$4.61M 0.01% 1076
2016
Q1
$45.1M Buy
2,122,551
+466,388
+28% +$7.64M 0.01% 865
2015
Q4
$38M Buy
1,656,163
+281,193
+20% +$7.24M 0.01% 944
2015
Q3
$27.6M Sell
1,374,970
-149,941
-10% -$4.56M 0.01% 1067
2015
Q2
$44.1M Buy
1,524,911
+240,208
+19% +$6.07M 0.01% 946
2015
Q1
$39.3M Buy
1,284,703
+549,384
+75% +$14.2M 0.01% 1003
2014
Q4
$12M Buy
+735,319
New +$10.4M ﹤0.01% 1818

Other funds holding CHRS